Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Spotlight Therapeutics

Main focus: In vivo gene therapies

Company stage: Pre-clinical

Diseases: Ocular diseases, haemoglobinopathies and immunooncology

Genome editing tool: CRISPR (undisclosed type)

Funding stage: Private

Location: San Francisco Bay Area, CA, USA

Website: https://www.spotlighttx.com/

Pipeline: https://www.spotlighttx.com/spotlighttx-platform

Spotlight Therapeutics is an early stage pre-clinical gene-editing company. Spotlight is focused on developing first-in-class in vivo gene-editing therapeutics. To do this it uses its proprietary technology platform Targeted Active Gene Editors (TAGE). The TAGE platform allows the company to address both delivery and in vivo CRISPR editing shortcomings.

Spotlight Therapeutics

Your Latest CMN News

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Company: Spotlight Therapeutics

Search CRISPR Medicine